Egetis Therapeutics

Focus: Egetis Therapeutics is a Swedish-based specialty pharmaceutical company focused on neurology and oncology programs in Phase 1-3 clinical development. The company operates as a public-stage biotech with a diversified pipeline across multiple therapeutic areas.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Egetis Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Egetis Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Tiratricol

Monocarboxylate Transporter 8 Deficiency

N/A

Clinical Trials (1)

NCT05911399Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency

N/A

Help build intelligence for Egetis Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline diversity with 9 programs across Phase 1-3, including two Phase 3 candidates (Calmangafodipir in colorectal cancer, Tiratricol in MCT8 deficiency) offering near-term catalysts
Focus on neurology and rare disease spaces provides differentiation and potential for orphan/breakthrough designations
Public-stage company status suggests infrastructure maturity and potential liquidity for employees

Watch Out For

Zero current job openings and no hiring data reported suggests minimal active expansion or potential organizational constraints
Limited commercial infrastructure apparent—no revenue-generating products and sparse information on team size or departmental structure creates uncertainty about growth trajectory

Generated by Claude from Egetis Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Calmangafodipir

Chemotherapy Induced Peripheral Neuropathy (CIPN)

PHASE_1

Clinical Trials (1)

NCT03430999SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Phase 1

PP100-01

Paracetamol Overdose

PHASE_1

Clinical Trials (1)

NCT03177395PP100-01 (Calmangafodipir) for Overdose of Paracetamol

Phase 1